BioTuesdays

Author - Melane Sampson

Mersana Therapeutics Logo
Markets

HCW cuts Mersana Therapeutics PT to $16 from $33

H.C. Wainwright slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $16 from $33 after the company disclosed a partial clinical hold on its lead clinical program targeting HER2 expressing cancers. The...

July 20, 2018
Autolus Logo
Markets

WB starts Autolus Therapeutics at OP; valuation of $38

William Blair launched coverage of Autolus Therapeutics (NASDAQ:AUTL) with an “outperform” rating and risk-adjusted valuation of roughly $38. The stock closed at $20.86 on July 17. “Based on our view, the company’s next...

July 18, 2018
Adamas Pharmaceuticals Logo
Markets

HCW starts Adamas Pharma at buy; PT $45

H.C. Wainwright launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with a “buy” rating and $45 price target. The stock closed at $27.06 on July 13. Adamas’ lead product, GOCOVRI, was approved in August 2017 in...

July 16, 2018
Krystal Biotech Logo
Markets

Leerink starts Krystal Biotech at buy; FVE $29

Leerink launched coverage of Krystal Biotech (NASDAQ:KRYS) with a “buy” rating and $29 fair value estimate. The stock closed at $15.07 on July 9. Krystal is developing novel gene therapies for skin diseases, with lead...

July 10, 2018
Epizyme Logo
Markets

Leerink cuts Epizyme to market perform and PT to $16

Leerink downgraded Epizyme (NASDAQ:EPZM) to “market perform” from “outperform” and lowered its price target to $16 from $24 after making extensive changes to its revenue forecasts for Epizyme’s only drug, tazemetostat...

July 3, 2018
Flex Pharma
Markets

Ladenburg cuts Flex Pharma to neutral, drops PT

Ladenburg Thalmann downgraded Flex Pharm (NASDAQ:FLKS) to “neutral” from “buy” without a price target after the company halted two Phase 2 trials. In afternoon trading on June 13, shares of Flex were quoted at $1.36...

June 13, 2018